Abstract
Protein stability of hypoxia-inducible factor (HIF) α subunits is regulated by the oxygen-sensing prolyl-4- hydroxylase domain (PHD) enzymes. Under oxygen-limited conditions, HIFα subunits are stabilized and form active HIF transcription factors that induce a large number of genes involved in adaptation to hypoxic conditions with physiological implications for erythropoiesis, angiogenesis, cardiovascular function and cellular metabolism. Oxygen-sensing is regulated by the co-substrate-dependent activity and hypoxia-inducible abundance of the PHD enzymes which trigger HIFα stability even under low oxygen conditions. Because HIFα itself is notoriously reluctant to the development of antagonists, an increase in PHD activity would offer an interesting alternative to the development of drugs that interfere specifically with the HIF signalling pathway. Interestingly, among the recently discovered PHD interacting proteins were not only novel downstream targets but also upstream regulators of PHDs. Their PHD isoform-specific interaction offers the possibility to target distinct PHD isoforms and their non-identical downstream signalling pathways. This review summarizes our current knowledge on PHD interacting proteins, including upstream regulators, chaperonins, scaffolding proteins, and novel downstream transcription factors.
Keywords: Asparaginyl hydroxylase, hypoxia, iron, oxidative decarboxylation, oxygen sensing, prolyl-4-hydroxylase, protein stability, succinate
Current Pharmaceutical Design
Title: HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Volume: 15 Issue: 33
Author(s): Roland H. Wenger, Gieri Camenisch, Daniel P. Stiehl and Dorthe M. Katschinski
Affiliation:
Keywords: Asparaginyl hydroxylase, hypoxia, iron, oxidative decarboxylation, oxygen sensing, prolyl-4-hydroxylase, protein stability, succinate
Abstract: Protein stability of hypoxia-inducible factor (HIF) α subunits is regulated by the oxygen-sensing prolyl-4- hydroxylase domain (PHD) enzymes. Under oxygen-limited conditions, HIFα subunits are stabilized and form active HIF transcription factors that induce a large number of genes involved in adaptation to hypoxic conditions with physiological implications for erythropoiesis, angiogenesis, cardiovascular function and cellular metabolism. Oxygen-sensing is regulated by the co-substrate-dependent activity and hypoxia-inducible abundance of the PHD enzymes which trigger HIFα stability even under low oxygen conditions. Because HIFα itself is notoriously reluctant to the development of antagonists, an increase in PHD activity would offer an interesting alternative to the development of drugs that interfere specifically with the HIF signalling pathway. Interestingly, among the recently discovered PHD interacting proteins were not only novel downstream targets but also upstream regulators of PHDs. Their PHD isoform-specific interaction offers the possibility to target distinct PHD isoforms and their non-identical downstream signalling pathways. This review summarizes our current knowledge on PHD interacting proteins, including upstream regulators, chaperonins, scaffolding proteins, and novel downstream transcription factors.
Export Options
About this article
Cite this article as:
Wenger H. Roland, Camenisch Gieri, Stiehl P. Daniel and Katschinski M. Dorthe, HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting, Current Pharmaceutical Design 2009; 15 (33) . https://dx.doi.org/10.2174/138161209789649411
DOI https://dx.doi.org/10.2174/138161209789649411 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs
Anti-Cancer Agents in Medicinal Chemistry Risk Profiles in Type 2 Diabetes (Metabolic Syndrome): Integration of IL-10 Polymorphisms and Laboratory Parameters to Identify Vascular Damages Related Complications
Current Pharmaceutical Design Modulation of Rack-1/PKCβII Signalling By Soluble AβPPα in SH-SY5Y Cells
Current Alzheimer Research Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Takotsubo Cardiomyopathy
Current Pharmaceutical Design Endoplasmic Reticulum Stress in Arterial Smooth Muscle Cells: A Novel Regulator of Vascular Disease
Current Cardiology Reviews mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science MicroRNAs in Aortic Disease
Current Topics in Medicinal Chemistry Anti-Hyperglycemic and Hypolipidemic Effects of Different Aloe vera (Aloe Barbadensis Miller) Extracts in the Management of Obesity and Diabetes
Current Nutrition & Food Science Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity
Current Medicinal Chemistry Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design Angiogenesis and the Heart
Recent Patents on Cardiovascular Drug Discovery Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases
Current Neurovascular Research The Role of iNOS in Chronic Inflammatory Processes In Vivo: Is it Damage-Promoting, Protective, or Active at all?
Current Molecular Medicine A Review of Sirt1 and Sirt1 Modulators in Cardiovascular and Metabolic Diseases
Recent Patents on Cardiovascular Drug Discovery